Madlaina Breuleux

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi Heregulins implicated in cellular functions other than receptor activation
    Madlaina Breuleux
    Novartis Pharma AG, Klybeckstrasse 125, WKL 125 12 59, 4002 Basel, Switzerland
    Mol Cancer Res 4:27-37. 2006
  2. ncbi Role of heregulin in human cancer
    M Breuleux
    Novartis Institutes for Biomedical Research NIBR, Oncology, WKL 125 12 59, Klybeckstrasse 141, 4002, Basel, Switzerland
    Cell Mol Life Sci 64:2358-77. 2007
  3. ncbi Optimal targeting of the mTORC1 kinase in human cancer
    Heidi A Lane
    Basilea Pharmaceutica International AG, Basel, Switzerland
    Curr Opin Cell Biol 21:219-29. 2009
  4. ncbi Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition
    Madlaina Breuleux
    Novartis Pharma AG, Novartis Institutes for BioMedical Research, Oncology, Basel, Switzerland
    Mol Cancer Ther 8:742-53. 2009
  5. ncbi The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer
    Anne Boulay
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Cancer Res 68:3743-51. 2008

Collaborators

Detail Information

Publications5

  1. ncbi Heregulins implicated in cellular functions other than receptor activation
    Madlaina Breuleux
    Novartis Pharma AG, Klybeckstrasse 125, WKL 125 12 59, 4002 Basel, Switzerland
    Mol Cancer Res 4:27-37. 2006
    ....
  2. ncbi Role of heregulin in human cancer
    M Breuleux
    Novartis Institutes for Biomedical Research NIBR, Oncology, WKL 125 12 59, Klybeckstrasse 141, 4002, Basel, Switzerland
    Cell Mol Life Sci 64:2358-77. 2007
    ..Disruption of the physiological balance between HRG ligands and their ErbB receptors is implicated in the formation of a variety of human cancers. The general mechanisms involved in HRG-induced tumorigenesis is discussed...
  3. ncbi Optimal targeting of the mTORC1 kinase in human cancer
    Heidi A Lane
    Basilea Pharmaceutica International AG, Basel, Switzerland
    Curr Opin Cell Biol 21:219-29. 2009
    ..Emphasis is given where possible to mTORC1 drug development decisions based on full clinical publications...
  4. ncbi Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition
    Madlaina Breuleux
    Novartis Pharma AG, Novartis Institutes for BioMedical Research, Oncology, Basel, Switzerland
    Mol Cancer Ther 8:742-53. 2009
    ..However, reduced cell viability could not be predicted from biochemical or cellular responses to mTORC1 inhibitors. These data could have implications for the clinical application of phosphatidylinositol 3-kinase/mTOR inhibitors...
  5. ncbi The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer
    Anne Boulay
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Cancer Res 68:3743-51. 2008
    ..In summary, we showed that Ret is a novel proliferative pathway interacting with ER signaling in vitro. Expression of Ret in primary breast tumors suggests that Ret might be a novel therapeutic target in breast cancer...